Strong Memorial Ranked Among Top Centers for Heart Pumps, Survival

Frank Rosinski ’s heart stopped three times and doctors were able to revive him. Doctors immediately transferred the Greece man to Strong Memorial Hospital for heart failure care by Upstate New York’s largest and most experienced team.
Source: University of Rochester Medical Center Press Releases - Category: Universities & Medical Training Authors: Source Type: news

Related Links:

In conclusion, this study identifies that administration of RTX can inhibit pressure overload-induced cardiac remodeling and dysfunction in mice, and suggest that RTX may be a promising drug for treating hypertrophic disease.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Discussion: Incomplete septal cirrhosis is an uncommon cause of non-cirrhotic portal hypertension. Its definition is not well known, morphological and pathophysiological. We have not found published cases of post-RT ascites secondary to this pathology, described as possibly associated with drugs, immune alterations, infections, hypercoagulability and genetic predisposition. PMID: 30897191 [PubMed - as supplied by publisher]
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research
Ventricular assist devices (VADs) are an important technological development for patients with end-stage heart failure, and approximately 50% of these patients require various additional cardiac procedures. Here we presente the case of a patient suffering from severe aortic insufficiency, aortic root dilatation, and an ascending aortic aneurysm with end-stage decompensated heart failure. We performed the Bentall procedure combined with a left VAD implantation during the same session. The postoperative period was uneventful for this patient, and he was discharged on the 32nd postoperative day. The heart failure sym...
Source: Brazilian Journal of Cardiovascular Surgery - Category: Cardiology Source Type: research
Congestive heart failure caused by silent ischemia and silent myocardial infarction : Diagnostic challenge in type 2 diabetes. Herz. 2019 Mar 21;: Authors: Valensi P, Meune C Abstract In asymptomatic patients with type 2 diabetes (T2D), the prevalence of silent myocardial infarction on routine electrocardiograms is about 4% while for silent myocardial ischemia it is 20-30%. Some studies showed that silent myocardial infarction is associated with an increased risk of incident heart failure (HF), whereas no prospective study has ever reported such a risk in patients with silent myocardial ...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
(MedPage Today) -- MOMENTUM 3 data confirms better safety for newer LVAD in advanced heart failure
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
Authors: Sztechman D, Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Zera T Abstract In the review we discuss the role of mineralocorticoid receptors (MRs) in regulation and pathological remodelling of the cardiovascular system and the therapeutic potential of pharmacological targeting of MRs in cardiovascular diseases. MRs are expressed in organs involved in cardiovascular homeostasis: brain, heart, kidneys and vessels. The excessive activation of MRs has deleterious effects on the cardiovascular system through sympatho-excitation, elevated salt appetite, and renal retention of salt with consequent p...
Source: Journal of Physiology and Pharmacology - Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research
We report a case of a 29-year old male with HF, dilated cardiomyopathy possibly related to myocarditis, and atrial fibrillation with reduced ejection fraction. Sacubitril/valsartan treatment was initiated after two years of standard treatment. In two years, therapy with sacubitril/valsartan led to persistence in sinus rhythm and progressive recovery of ejection fraction, functionality, and reduction of cardiac volumes. The patient is currently in good condition and has suspended diuretic therapy in the last six months. PMID: 30895821 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
We reported a case series of ten patients with stable chronic HF and LVEF ≤35% (mean age: 64 ± 8 years; 30% female), referred to our outpatient HF clinic, treated with sacubitril/valsartan, in whom the global amelioration of NYHA class and LVEF coupled a clinically significant decrease in BNP levels and a reduction of loop diuretic dose. Average sacubitril/valsartan daily dose was 220 mg. The median duration of treatment was fifteen months (range: 6-21 months). Seventy per cent of patients exhibited an improvement in the exercise tolerance, as indicated by the change in NYHA class. There was ...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Management of patient with heart failure: Italian "field practice" experience on sacubitril/valsartan. Curr Med Res Opin. 2019 Mar 21;:1 Authors: De Angelis G PMID: 30894037 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
In conclusion, our case showed a strong beneficial effect of Sacubitril/Valsartan on reverse remodeling and LVEF beyond the benefits of concomitant optimal medical therapy. This result is particular noteworthy because it was obtained although patient wasn't able to reach the full dose of the drug. Physician should always consider this drug effect when more demanding therapeutic strategies are needed for their HF patients. PMID: 30894032 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Cardiology | Greece Health | Heart | Heart Failure | Hospitals | Universities & Medical Training